Search results for "Matrix Metalloproteinase 9"

showing 3 items of 73 documents

Retinoids induce MMP-9 expression through RARalpha during mammary gland remodeling.

2007

Retinoic acid (RA) is a signaling molecule in the morphogenesis of the mammary gland, modulating the expression of matrix metalloproteinases (MMPs). The aim of this paper was to study the role of RA during weaning, which consists of three events: apoptosis of the secretory cells, degradation of the extracellular matrix, and adipogenesis. CRABP II and CRBP-1 carrier proteins increased significantly during weaning compared with lactating glands but reverted to control values after the litter resuckled. The effects of RA are mediated by the nuclear receptors RARalpha, RARbeta, RARgamma, and RXRalpha, which underwent an increase in protein levels during weaning. In an attempt to elucidate the R…

medicine.medical_specialtyRetinyl EstersTime FactorsPhysiologymedicine.drug_classReceptors Retinoic AcidEndocrinology Diabetes and MetabolismMammary glandMorphogenesisRetinoic acidApoptosisTretinoinWeaningMatrix metalloproteinaseBiologyStromelysin 1chemistry.chemical_compoundRetinoidsMammary Glands AnimalPregnancyPhysiology (medical)Internal medicinemedicineAnimalsLactationInvolution (medicine)RetinoidRNA MessengerRats WistarVitamin AMammary gland involutionAdipogenesisRetinoic Acid Receptor alphaRetinol-Binding Proteins CellularMatrix MetalloproteinasesExtracellular MatrixRatsRetinol-Binding Proteinsmedicine.anatomical_structureEndocrinologychemistryMatrix Metalloproteinase 9Matrix Metalloproteinase 2FemaleDiterpenesSignal TransductionAmerican journal of physiology. Endocrinology and metabolism
researchProduct

Acute exercise induced changes in rat skeletal muscle mRNAs and proteins regulating type IV collagen content

2001

This experiment tested the hypothesis that running-induced damage to rat skeletal muscle causes changes in synthesis and degradation of basement membrane type IV collagen and to proteins regulating its degradation. Samples from soleus muscle and red and white parts of quadriceps femoris muscle (MQF) were collected 6 h or 1, 2, 4, or 7 days after downhill running. Increased muscle β-glucuronidase activity indicated greater muscle damage in the red part of MQF than in the white part of MQF or soleus. In the red part of MQF, type IV collagen expression was upregulated at the pretranslational level and the protein concentration decreased, whereas matrix metalloproteinase-2 (MMP-2), a protein th…

medicine.medical_specialtyTime FactorsTranscription GeneticPhysiologyPhysical ExertionMatrix metalloproteinaseBiologyRunningType IV collagenPhysiology (medical)Internal medicineGene expressionmedicineAnimalsRNA MessengerRats WistarMuscle SkeletalGlucuronidaseSoleus muscleBasement membranechemistry.chemical_classificationTissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-1Skeletal muscleTissue inhibitor of metalloproteinaseRatsmedicine.anatomical_structureEndocrinologyGene Expression RegulationMatrix Metalloproteinase 9chemistryProtein BiosynthesisMuscle Fibers Fast-TwitchMatrix Metalloproteinase 2FemaleCollagenGlycoproteinAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology
researchProduct

Protein kinase C-inhibiting properties of the losartan metabolite EXP3179 make the difference.

2009

The inhibition of the renin-angiotensin axis with the angiotensin II (ATII) receptor blockers, such as losartan, candesartan, and valsartan, has been demonstrated, similar to angiotensin-converting enzyme inhibitors, to reduce mortality in patients with arterial hypertension, chronic congestive heart failure, and acute myocardial infarction.1 Initially, the ATII receptor antagonist losartan helped to demonstrate new classes of ATII receptors and substantially expanded our knowledge about the cardiovascular effects of the renin-angiotensin-aldosterone system and its effector peptide ATII. Researchers dealing with this compound soon revealed that, beyond its antihypertensive effects attribute…

medicine.medical_specialtymedicine.drug_classMetabolitePharmacologyLosartanchemistry.chemical_compoundInternal medicineInternal MedicinemedicineHumansReceptorProtein Kinase CPhagocytesNADPH oxidasebiologyNADPH OxidasesReceptor antagonistAngiotensin IICandesartanEndocrinologyLosartanchemistryValsartanMatrix Metalloproteinase 9Hypertensionbiology.proteinAngiotensin II Type 1 Receptor Blockersmedicine.drugHypertension (Dallas, Tex. : 1979)
researchProduct